0001144204-15-022328.txt : 20150410 0001144204-15-022328.hdr.sgml : 20150410 20150410200626 ACCESSION NUMBER: 0001144204-15-022328 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150408 FILED AS OF DATE: 20150410 DATE AS OF CHANGE: 20150410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytosorbents Corp CENTRAL INDEX KEY: 0001175151 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980373793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 973-329-8885 MAIL ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: MedaSorb Technologies CORP DATE OF NAME CHANGE: 20060807 FORMER COMPANY: FORMER CONFORMED NAME: GILDER ENTERPRISES INC DATE OF NAME CHANGE: 20020611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BLOCH KATHLEEN P. CENTRAL INDEX KEY: 0001409212 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36792 FILM NUMBER: 15765593 MAIL ADDRESS: STREET 1: 3 PERSHING COURT CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 4 1 v407031_4.xml OWNERSHIP DOCUMENT X0306 4 2015-04-08 0 0001175151 Cytosorbents Corp CTSO 0001409212 BLOCH KATHLEEN P. C/O CYTOSORBENTS CORPORATION 7 DEER PARK DRIVE, SUITE K MONMOUTH JUNCTION NJ 08852 0 1 0 0 Chief Financial Officer Common Stock 2015-04-08 4 A 0 110000 0 A 110000 D Stock Option (right to buy) 8.07 2015-04-08 4 A 0 56000 0 A 2025-04-08 Common Stock 56000 56000 D These shares represent restricted stock units and will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan. Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, 45% of which vest upon achieving 2015 budgeted revenues and not exceeding budgeted operating expenses; 30% of which vest upon achievement of multiple clinical trial objectives in calendar year 2015, as determined in the discretion of the Board of Directors; 15% of which vests upon demonstration of reasonable progress in the U.S. regulatory approval of one of CytoSorbents Corporation's products, as determined in the discretion of the Board of Directors; and 10% of which vests upon achievement of one or more new major strategic partnerships, as determined in the discretion of the Board of Directors. /s/ Kathleen P. Bloch 2015-04-10